Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: anastrozole|DRUG: exemestane|DRUG: letrozole|DRUG: sorafenib tosylate|OTHER: placebo
Sponsor: Mayo Clinic
Collaborators: National Cancer Institute (NCI)